DOM FIGURE 1 Effect of single exposure to AZD1656 or PF-04991532 on blood glucose and insulin and liver gene expression.

Male C57BL/6 mice were treated with vehicle or AZD1656 (A,E) at the doses indicated 2h before an oral glucose tolerance test or with PF-04991532 (B,F) 1h before the oral glucose tolerance test. C,G. Changes in blood glucose (C) and insulin (G) after treatment with AZD1656 or PF-04991532 before glucose gavage. D. Blood glucose, area under the curve. H. Plasma insulin, area under the curve. I. Liver mRNA levels for the indicated genes normalized to TATA-Binding Protein (TBP) and to vehicle controls. Means ± SEM, n=8, * P < 0.05 relative to vehicle, except for C,G relative to time zero.

以雄性C57BL/6小鼠为实验对象，其中一组给予赋形剂或AZD1656处理（对应A、E图），给药剂量如标注所示，于口服葡萄糖耐量试验前2小时给药；另一组给予PF-04991532处理（对应B、F图），于口服葡萄糖耐量试验前1小时给药。C、G图分别展示经AZD1656或PF-04991532预处理后行葡萄糖灌胃的小鼠血糖与胰岛素水平的变化情况。D图展示血糖水平及其曲线下面积。H图展示血浆胰岛素水平及其曲线下面积。I图展示以TATA结合蛋白（TATA-Binding Protein, TBP）为内参基因、以赋形剂处理组为对照时，各标注基因的肝脏mRNA表达水平。所有数据以平均值±标准误（SEM）表示，每组样本量n=8；与赋形剂处理组相比，*P<0.05，其中C、G图的显著性比较以时间零点为基准。